NCT00215995View on ClinicalTrials.gov

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Esophageal CancerGastric Cancer
Interventions
DRUG

Cisplatin

As outlined in Detailed Description

DRUG

Irinotecan

As outlined in Detailed Description

DRUG

ZD 1839

As outlined in Detailed Description

Trial Locations (3)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

00732

Ponce School of Medicine, Ponce

00936-5067

University of Puetro Rico Cancer Center, San Juan

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00215995 - Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas | Biotech Hunter | Biotech Hunter